--- title: "Livanova | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 390.6 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294946138.md" datetime: "2026-08-05T10:07:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294946138.md) - [en](https://longbridge.com/en/news/294946138.md) - [zh-HK](https://longbridge.com/zh-HK/news/294946138.md) --- # Livanova | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 390.6 M Revenue: As of FY2026 Q2, the actual value is USD 390.6 M, beating the estimate of USD 380.58 M. EPS: As of FY2026 Q2, the actual value is USD 1.93, beating the estimate of USD 0.76. EBIT: As of FY2026 Q2, the actual value is USD 25.7 M. ### Overall Revenue LivaNova PLC reported total revenue of $390.6 million for the second quarter ended June 30, 2026, marking a 10.8% increase on a reported basis and a 9.8% increase on a constant-currency basis compared to $352.5 million in the prior-year period. Total revenue for the six months ended June 30, 2026, was $752.8 million, an increase of 12.5% on a reported basis and 10.4% on a constant-currency basis, compared to $669.4 million for the same period in 2025. ### Segment Revenue #### Cardiopulmonary Revenue for the second quarter of 2026 was $221.6 million, an 11.2% increase reported and 9.9% constant-currency from $199.3 million in Q2 2025. For the six months, Cardiopulmonary revenue reached $430.2 million, an increase of 14.5% reported and 11.8% constant-currency from $375.6 million in the prior year. U.S. Cardiopulmonary revenue for Q2 2026 was $72.8 million, a 2.2% increase from $71.2 million in Q2 2025. For the six months, U.S. revenue was $142.1 million, up 7.6% from $132.1 million. Europe Cardiopulmonary revenue for Q2 2026 was $62.0 million, a 26.3% reported increase and 23.8% constant-currency increase from $49.0 million in Q2 2025. For the six months, Europe revenue was $119.3 million, up 27.5% reported and 20.8% constant-currency from $93.6 million. Rest of World Cardiopulmonary revenue for Q2 2026 was $86.8 million, a 9.9% reported increase and 8.4% constant-currency increase from $79.0 million in Q2 2025. For the six months, Rest of World revenue was $168.9 million, up 12.6% reported and 10.0% constant-currency from $150.0 million. #### Neuromodulation Revenue for the second quarter of 2026 was $166.9 million, an increase of 10.1% reported and 9.5% constant-currency from $151.7 million in Q2 2025. For the six months, Neuromodulation revenue was $318.7 million, up 9.7% reported and 8.6% constant-currency from $290.6 million in the prior year. U.S. Neuromodulation revenue for Q2 2026 was $126.6 million, an 8.0% increase from $117.2 million in Q2 2025. For the six months, U.S. revenue was $242.0 million, up 7.3% from $225.6 million. Europe Neuromodulation revenue for Q2 2026 was $19.9 million, a 12.0% reported increase and 9.7% constant-currency increase from $17.7 million in Q2 2025. For the six months, Europe revenue was $38.2 million, up 16.0% reported and 9.6% constant-currency from $32.9 million. Rest of World Neuromodulation revenue for Q2 2026 was $20.5 million, a 22.8% reported increase and 20.4% constant-currency increase from $16.7 million in Q2 2025. For the six months, Rest of World revenue was $38.6 million, up 20.2% reported and 17.0% constant-currency from $32.1 million. #### Other Revenue Revenue for the second quarter of 2026 was $2.1 million, a 30.6% reported increase and 27.7% constant-currency increase from $1.6 million in Q2 2025. For the six months, Other Revenue was $3.9 million, up 20.4% reported and 13.5% constant-currency from $3.2 million. ### Operational Metrics (GAAP) - **Gross Profit:** For Q2 2026, GAAP gross profit was $273.7 million (70.1% of net revenue), compared to $239.0 million (67.8% of net revenue) in Q2 2025. For the six months, GAAP gross profit was $517.4 million (68.7% of net revenue) in 2026, compared to $455.2 million (68.0% of net revenue) in 2025. - **Operating Income:** GAAP operating income for Q2 2026 was $49.5 million (12.7% of net revenue), compared to $54.2 million (15.4% of net revenue) in Q2 2025. For the six months, GAAP operating income was $91.0 million (12.1% of net revenue) in 2026, compared to $102.8 million (15.4% of net revenue) in 2025. - **Net Income:** GAAP net income for Q2 2026 was $108.6 million (27.8% of net revenue), compared to $27.2 million (7.7% of net revenue) in Q2 2025. For the six months, GAAP net income was $130.9 million (17.4% of net revenue) in 2026, compared to a net loss of -$300.2 million (-44.8% of net revenue) in 2025. - **Selling, General, and Administrative (SG&A):** GAAP SG&A expenses were $158.1 million (40.5% of net revenue) in Q2 2026, up from $137.8 million (39.1% of net revenue) in Q2 2025. For the six months, GAAP SG&A was $301.7 million (40.1% of net revenue) in 2026, compared to $266.9 million (39.9% of net revenue) in 2025. - **Research and Development (R&D):** GAAP R&D expenses were $53.7 million (13.7% of net revenue) in Q2 2026, up from $47.2 million (13.4% of net revenue) in Q2 2025. For the six months, GAAP R&D was $112.4 million (14.9% of net revenue) in 2026, compared to $85.1 million (12.7% of net revenue) in 2025. ### Operational Metrics (Adjusted) - **Adjusted Gross Profit:** Adjusted gross profit for Q2 2026 was 71.0% of net revenue, compared to 68.9% in Q2 2025. For the six months, adjusted gross profit was 69.7% of net revenue in 2026, compared to 68.9% in 2025. - **Adjusted Operating Income:** Adjusted operating income for Q2 2026 was $90.8 million (23.2% of net revenue), compared to $77.4 million (21.9% of net revenue) in Q2 2025. For the six months, adjusted operating income was $161.9 million (21.5% of net revenue) in 2026, compared to $141.9 million (21.2% of net revenue) in 2025. - **Adjusted Net Income:** Adjusted net income for Q2 2026 was $71.0 million (18.2% of net revenue), compared to $57.4 million (16.3% of net revenue) in Q2 2025. For the six months, adjusted net income was $125.5 million (16.7% of net revenue) in 2026, compared to $105.5 million (15.8% of net revenue) in 2025. - **Adjusted SG&A:** Adjusted SG&A expenses were $136.7 million (35.0% of net revenue) in Q2 2026, compared to $121.4 million (34.4% of net revenue) in Q2 2025. For the six months, adjusted SG&A was $265.6 million (35.3% of net revenue) in 2026, compared to $237.1 million (35.4% of net revenue) in 2025. - **Adjusted R&D:** Adjusted R&D expenses were $50.0 million (12.8% of net revenue) in Q2 2026, compared to $44.0 million (12.5% of net revenue) in Q2 2025. For the six months, adjusted R&D was $97.1 million (12.9% of net revenue) in 2026, compared to $82.2 million (12.3% of net revenue) in 2025. ### Cash Flow - **Net Cash Provided by Operating Activities:** For Q2 2026, net cash provided by operating activities was $66.6 million. For the six months ended June 30, 2026, it was $81.8 million, compared to $86.9 million in the prior-year period. - **Adjusted Free Cash Flow:** Adjusted free cash flow for Q2 2026 was $45.5 million. - **Purchases of Property, Plant, and Equipment:** For Q2 2026, purchases of property, plant, and equipment amounted to -$31.6 million. For the six months ended June 30, 2026, these purchases were -$45.8 million, compared to -$25.9 million in the prior-year period. ### Unique Metrics and Key Developments LivaNova PLC entered into a long-term agreement with Thermo Fisher Scientific to enhance oxygenator component supply, aiming to increase manufacturing output and meet customer demand, bolstering the Cardiopulmonary supply chain. Data indicated that the PolySync™ programming algorithm increased the cumulative apnea-hypopnea index response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea, improving response and expanding the impact of proximal hypoglossal nerve stimulation therapy over time. A favorable ruling from the Italian tax authority led to the recognition of a discrete tax benefit of €81.8 million ($95.4 million) related to the deductibility of a previously recorded environmental liability. ### Outlook / Guidance LivaNova PLC raised its full-year 2026 revenue growth range to 8% to 9% on a constant-currency basis, with foreign currency expected to be a tailwind of approximately 1%. The company also raised its adjusted diluted earnings per share range to $4.30 to $4.40. However, LivaNova PLC lowered its full-year 2026 adjusted free cash flow range to $140 million to $160 million due to increased strategic investments in Cardiopulmonary capacity expansion, innovation, and IT infrastructure. ### Related Stocks - [LIVN.US](https://longbridge.com/en/quote/LIVN.US.md) ## Related News & Research - [LivaNova Chief Innovation Officer Ahmet Tezel disposes of shares worth $435,409.36](https://longbridge.com/en/news/295838616.md) - [Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock](https://longbridge.com/en/news/295951890.md) - [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md) - [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/296137926.md) - [Syn updates 2026 financial calendar for interim results release](https://longbridge.com/en/news/296331010.md)